← Back to Search

Virus Therapy

Cohort for Solid Organ Cancer

Phase 1
Waitlist Available
Led By Andrew Brenner, MD
Research Sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights

Study Summary

Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer

Eligible Conditions
  • Solid Organ Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)

Trial Design

1Treatment groups
Experimental Treatment
Group I: CohortExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ofranergene obadenovec
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Vascular Biogenics Ltd. operating as VBL TherapeuticsLead Sponsor
11 Previous Clinical Trials
1,633 Total Patients Enrolled
Andrew Brenner, MDPrincipal InvestigatorUTHSC- CTRC and Institute for Drug Development
3 Previous Clinical Trials
201 Total Patients Enrolled
Pierre Triozzi, Dr.Principal InvestigatorThe Cleveland Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
2007. "A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00559117.
All > Uti
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top